AYTU BIOPHARMA, INC Costs and Expenses
AYTU BIOPHARMA, INC (AYTU) reported Costs and Expenses of $39.15 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2021-05-17
- AYTU BIOPHARMA, INC costs and expenses for the quarter ending 2021-03-31 was $39.15M, a 202.31% increase year-over-year.
- AYTU BIOPHARMA, INC costs and expenses for the quarter ending 2020-12-31 was $20.72M, a 154.50% increase year-over-year.
- AYTU BIOPHARMA, INC costs and expenses for the quarter ending 2020-03-31 was $12.95M.
- AYTU BIOPHARMA, INC costs and expenses for the quarter ending 2019-12-31 was $8.14M.
- AYTU BIOPHARMA, INC costs and expenses for fiscal 2013 was $54.16K, a 6.78% decline from fiscal 2012.
- AYTU BIOPHARMA, INC costs and expenses for fiscal 2012 was $58.11K, a 56.51% decline from fiscal 2011.
- AYTU BIOPHARMA, INC costs and expenses for fiscal 2011 was $133.62K.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month | Costs and Expenses 81 month | Costs and Expenses 84 month | Costs and Expenses 87 month | Costs and Expenses 90 month | Costs and Expenses 93 month | Costs and Expenses 96 month | Costs and Expenses 99 month | Costs and Expenses 102 month | Costs and Expenses 105 month | Costs and Expenses 108 month | Costs and Expenses 111 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-03-31 | $39.15M 10-Q · filed 2021-05-17 | $59.87M derived: sum of 2 quarters · filed 2021-05-17 | $76.95M 10-Q · filed 2021-05-17 | ||||||||||||
| 2020-12-31 | $20.72M 10-Q · filed 2021-02-11 | $37.80M 10-Q · filed 2021-02-11 | |||||||||||||
| 2020-03-31 | $12.95M 10-Q · filed 2021-05-17 | $21.09M derived: sum of 2 quarters · filed 2021-05-17 | $27.27M 10-Q · filed 2021-05-17 | ||||||||||||
| 2019-12-31 | $8.14M 10-Q · filed 2021-02-11 | $14.32M 10-Q · filed 2021-02-11 | |||||||||||||
| 2015-03-31 | $1.83M 10-Q · filed 2015-05-19 | $5.56M 10-Q · filed 2015-05-19 | |||||||||||||
| 2015-02-28 | $9.40K 10-Q · filed 2015-04-15 | $24.69K 10-Q · filed 2015-04-15 | |||||||||||||
| 2014-11-30 | $15.29K 10-Q · filed 2015-01-12 | ||||||||||||||
| 2014-05-31 | $12.13K 10-Q · filed 2014-07-10 | $47.70K 10-Q · filed 2014-07-10 | $596.23K 10-Q · filed 2014-07-10 | ||||||||||||
| 2014-03-31 | $2.00M 10-Q · filed 2015-05-19 | $4.43M 10-Q · filed 2015-05-19 | |||||||||||||
| 2014-02-28 | $20.56K 10-Q · filed 2015-04-15 | $35.57K 10-Q · filed 2015-04-15 | $44.64K derived: sum of 3 quarters · filed 2015-04-15 | $58.35K derived: sum of 4 quarters · filed 2015-04-15 | $584.10K 10-Q · filed 2014-04-11 | ||||||||||
| 2013-11-30 | $15.01K 10-Q · filed 2015-01-12 | $24.08K derived: sum of 2 quarters · filed 2015-01-12 | $37.79K derived: sum of 3 quarters · filed 2015-01-12 | $50.34K derived: sum of 4 quarters · filed 2015-01-12 | $563.54K 10-Q · filed 2014-01-10 | ||||||||||
| 2013-08-31 | $9.07K derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-26 | $22.78K derived: sum of 2 quarters · filed 2014-11-26 | $35.33K derived: sum of 3 quarters · filed 2014-11-26 | $54.16K 10-K · filed 2014-11-26 | $548.53K 10-K · filed 2014-11-26 | ||||||||||
| 2013-05-31 | $13.71K 10-Q · filed 2014-07-10 | $26.26K derived: sum of 2 quarters · filed 2014-04-11 | $45.09K 10-Q · filed 2014-07-10 | $64.01K derived: sum of 4 quarters · filed 2014-11-26 | $539.46K 10-Q · filed 2013-06-28 | ||||||||||
| 2013-02-28 | $12.55K 10-Q · filed 2014-04-11 | $31.38K 10-Q · filed 2014-04-11 | $50.30K derived: sum of 3 quarters · filed 2014-11-26 | $61.39K derived: sum of 4 quarters · filed 2014-11-26 | $525.75K 10-Q · filed 2013-04-15 | ||||||||||
| 2012-11-30 | $18.83K 10-Q · filed 2014-01-10 | $37.75K derived: sum of 2 quarters · filed 2014-11-26 | $48.84K derived: sum of 3 quarters · filed 2014-11-26 | $58.06K derived: sum of 4 quarters · filed 2014-11-26 | $513.20K 10-Q · filed 2013-01-14 | ||||||||||
| 2012-08-31 | $18.92K derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-26 | $30.01K derived: sum of 2 quarters · filed 2014-11-26 | $39.23K derived: sum of 3 quarters · filed 2014-11-26 | $58.11K 10-K · filed 2014-11-26 | $494.37K 10-K · filed 2012-11-29 | ||||||||||
| 2012-05-31 | $11.09K 10-Q · filed 2012-06-26 | $20.31K derived: sum of 2 quarters · filed 2013-06-28 | $39.19K 10-Q · filed 2013-06-28 | $475.45K 10-Q · filed 2012-06-26 | |||||||||||
| 2012-02-29 | $9.22K 10-Q · filed 2012-04-12 | $28.10K 10-Q · filed 2013-04-15 | $464.36K 10-Q · filed 2012-04-12 | ||||||||||||
| 2012-02-28 | $9.22K 10-Q · filed 2013-04-15 | $28.10K derived: sum of 2 quarters · filed 2013-04-15 | $98.83K derived: sum of 3 quarters · filed 2013-04-15 | $118.85K derived: sum of 4 quarters · filed 2013-04-15 | |||||||||||
| 2011-11-30 | $18.88K 10-Q · filed 2013-01-14 | $89.61K derived: sum of 2 quarters · filed 2013-01-14 | $109.63K derived: sum of 3 quarters · filed 2013-01-14 | $135.94K derived: sum of 4 quarters · filed 2013-01-14 | $455.14K 10-Q · filed 2011-12-23 | ||||||||||
| 2011-08-31 | $70.73K derived: 10-K 12 month − 10-Q 9 month · filed 2012-11-29 | $90.75K derived: sum of 2 quarters · filed 2012-11-29 | $117.07K derived: sum of 3 quarters · filed 2012-11-29 | $133.62K 10-K · filed 2012-11-29 | |||||||||||
| 2011-05-31 | $20.02K 10-Q · filed 2012-06-26 | $46.33K derived: sum of 2 quarters · filed 2012-06-26 | $62.88K 10-Q · filed 2012-06-26 | ||||||||||||
| 2011-02-28 | $26.31K 10-Q · filed 2012-04-12 | $42.86K 10-Q · filed 2012-04-12 | |||||||||||||
| 2010-11-30 | $16.55K 10-Q · filed 2011-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |